CY1123260T1 - Ενα αλας νατριου του ν-((1,2,3,5,6,7-eξaϋδpo-s-inδaken-4-υλ)καρβαμοϋλ)-1-ισοπροπυλ-1η-πυραζολο-3-σουλφοναμιδιου - Google Patents

Ενα αλας νατριου του ν-((1,2,3,5,6,7-eξaϋδpo-s-inδaken-4-υλ)καρβαμοϋλ)-1-ισοπροπυλ-1η-πυραζολο-3-σουλφοναμιδιου

Info

Publication number
CY1123260T1
CY1123260T1 CY20201100756T CY201100756T CY1123260T1 CY 1123260 T1 CY1123260 T1 CY 1123260T1 CY 20201100756 T CY20201100756 T CY 20201100756T CY 201100756 T CY201100756 T CY 201100756T CY 1123260 T1 CY1123260 T1 CY 1123260T1
Authority
CY
Cyprus
Prior art keywords
indaken
sulfonamide
pyrazole
carbamoyl
isopropyl
Prior art date
Application number
CY20201100756T
Other languages
English (en)
Inventor
David Miller
Angus Macleod
Susana Del Rio Gancedo
Samuel Alexander STRATFORD
Original Assignee
Inflazome Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inflazome Limited filed Critical Inflazome Limited
Publication of CY1123260T1 publication Critical patent/CY1123260T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αφορά ένα άλας νατρίου του Ν-((1,2,3,5,6,7-εξαϋδρο-s-ινδακεν-4-υλο) καρβαμοϋλ)-1-ισοπροπυλ-1Η-πυραζολο-3-σουλφοναμιδίου και υδρίτες, επιδιαλυτώματα και πολυμορφικές μορφές αυτού. Η παρούσα εφεύρεση αφορά περαιτέρω φαρμακευτικές συνθέσεις που περιλαμβάνουν αυτήν την ένωση και τη χρήση αυτής της ένωσης στη θεραπεία και πρόληψη ιατρικών διαταραχών και νόσων, πλέον συγκεκριμένα δια αναστολής της NLRP3.
CY20201100756T 2018-04-23 2020-08-12 Ενα αλας νατριου του ν-((1,2,3,5,6,7-eξaϋδpo-s-inδaken-4-υλ)καρβαμοϋλ)-1-ισοπροπυλ-1η-πυραζολο-3-σουλφοναμιδιου CY1123260T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1806578.9A GB201806578D0 (en) 2018-04-23 2018-04-23 Novel compound
PCT/EP2019/060311 WO2019206871A1 (en) 2018-04-23 2019-04-23 A sodium salt of n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1 -isopropyl-1 h-pyrazole-3-sulfonamide

Publications (1)

Publication Number Publication Date
CY1123260T1 true CY1123260T1 (el) 2021-12-31

Family

ID=62236309

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100756T CY1123260T1 (el) 2018-04-23 2020-08-12 Ενα αλας νατριου του ν-((1,2,3,5,6,7-eξaϋδpo-s-inδaken-4-υλ)καρβαμοϋλ)-1-ισοπροπυλ-1η-πυραζολο-3-σουλφοναμιδιου

Country Status (27)

Country Link
US (2) US10973803B2 (el)
EP (2) EP3606909B1 (el)
JP (1) JP7382958B2 (el)
KR (1) KR20210005589A (el)
CN (1) CN112020495B (el)
AR (1) AR114827A1 (el)
AU (1) AU2019257973A1 (el)
BR (1) BR112020021650A2 (el)
CA (1) CA3097832A1 (el)
CY (1) CY1123260T1 (el)
DK (1) DK3606909T3 (el)
ES (1) ES2811228T3 (el)
GB (1) GB201806578D0 (el)
HR (1) HRP20201263T1 (el)
HU (1) HUE050369T2 (el)
LT (1) LT3606909T (el)
MA (2) MA48051B1 (el)
MD (1) MD3606909T2 (el)
ME (1) ME03822B (el)
MX (1) MX2020011196A (el)
PL (1) PL3606909T3 (el)
PT (1) PT3606909T (el)
RS (1) RS60646B1 (el)
SI (1) SI3606909T1 (el)
TW (1) TW201943704A (el)
UY (1) UY38186A (el)
WO (1) WO2019206871A1 (el)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20190356A (es) 2017-01-23 2019-11-20 Genentech Inc Compuestos químicos como inhibidores de la actividad de la interleuquina-1
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
US11370776B2 (en) 2017-07-07 2022-06-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
JP2020531448A (ja) 2017-08-15 2020-11-05 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
WO2019034692A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
JP2020531453A (ja) 2017-08-15 2020-11-05 インフレイゾーム リミテッド Ｎｌｒｐ３阻害剤としてのスルホニルウレアおよびスルホニルチオウレア
US11518739B2 (en) 2017-08-15 2022-12-06 Inflazome Limited Sulfonamide carboxamide compounds
EP3707134A1 (en) 2017-11-09 2020-09-16 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019166629A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166627A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166632A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
US11884645B2 (en) 2018-03-02 2024-01-30 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
EP3823726A1 (en) 2018-07-20 2021-05-26 F. Hoffmann-La Roche SA Sulfonylurea compounds as inhibitors of interleukin-1 activity
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
JP2023501319A (ja) * 2019-11-07 2023-01-18 インフレイゾーム リミテッド 神経変性疾患の処置および予防
WO2021089781A1 (en) * 2019-11-07 2021-05-14 Inflazome Limited Treatment or prevention of psychiatric brain disorders using the nlrp3 inhibitor n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1 -isopropyl-1 h-pyrazole-3-sulfonamide
CN114599356A (zh) * 2019-11-07 2022-06-07 英夫拉索姆有限公司 自身炎症性病症的治疗
GB201916237D0 (en) * 2019-11-07 2019-12-25 Inflazome Ltd Novel treatment
EP4054563A1 (en) 2019-11-07 2022-09-14 Inflazome Limited Treatment and prevention of neuroinflammation or an inflammatory brain disorder
WO2021089776A1 (en) * 2019-11-07 2021-05-14 Inflazome Limited Treatment and prevention of a traumatic brain disorder
WO2022023907A1 (en) 2020-07-31 2022-02-03 Novartis Ag Methods of selecting and treating patients at elevated risk of major adverse cardiac events

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4802908A (en) * 1987-01-22 1989-02-07 E. I. Du Pont De Nemours And Company Herbicidal 2-(1H)-pyrazinones
WO2001019390A1 (en) * 1999-09-14 2001-03-22 Pfizer Products Inc. Combination treatment with il-1ra and diaryl sulphonyl urea compounds
WO2013031931A1 (ja) * 2011-09-02 2013-03-07 協和発酵キリン株式会社 ケモカイン受容体活性調節剤
US10538487B2 (en) * 2015-02-16 2020-01-21 The University Of Queensland Sulfonylureas and related compounds and use of same
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
BR112018016671A2 (pt) 2016-02-16 2018-12-26 The University Of Queensland sulfonilureias e compostos relacionados e uso do mesmo
EP3872070A1 (en) 2016-04-18 2021-09-01 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
ES2940611T3 (es) 2016-04-18 2023-05-09 Novartis Ag Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
EP3272739A1 (en) 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes

Also Published As

Publication number Publication date
WO2019206871A1 (en) 2019-10-31
MA48051B1 (fr) 2020-08-31
EP3606909B1 (en) 2020-05-27
LT3606909T (lt) 2020-10-12
US20210315862A1 (en) 2021-10-14
TW201943704A (zh) 2019-11-16
EP3606909A1 (en) 2020-02-12
HUE050369T2 (hu) 2020-11-30
PL3606909T3 (pl) 2020-11-16
AU2019257973A1 (en) 2020-11-19
MX2020011196A (es) 2020-11-13
CA3097832A1 (en) 2019-10-31
BR112020021650A2 (pt) 2021-01-26
RS60646B1 (sr) 2020-09-30
EP3722281A1 (en) 2020-10-14
PT3606909T (pt) 2020-07-09
JP7382958B2 (ja) 2023-11-17
ES2811228T3 (es) 2021-03-11
UY38186A (es) 2019-11-29
CN112020495B (zh) 2024-05-17
MD3606909T2 (ro) 2020-08-31
KR20210005589A (ko) 2021-01-14
JP2021522195A (ja) 2021-08-30
US10973803B2 (en) 2021-04-13
DK3606909T3 (da) 2020-08-24
HRP20201263T1 (hr) 2021-02-05
SI3606909T1 (sl) 2020-09-30
US20200237723A1 (en) 2020-07-30
AR114827A1 (es) 2020-10-21
ME03822B (me) 2021-04-20
MA51082A (fr) 2021-05-19
GB201806578D0 (en) 2018-06-06
CN112020495A (zh) 2020-12-01

Similar Documents

Publication Publication Date Title
CY1123260T1 (el) Ενα αλας νατριου του ν-((1,2,3,5,6,7-eξaϋδpo-s-inδaken-4-υλ)καρβαμοϋλ)-1-ισοπροπυλ-1η-πυραζολο-3-σουλφοναμιδιου
MX2021004431A (es) Procesos novedosos.
CY1124432T1 (el) Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη
CY1124257T1 (el) N-[4-ΦΘOPO-5-[[(2S,4S)-2-MEΘYΛO-4-[(5-MEΘYΛO-1,2,4-ΟΞAΔIAZOΛ-3-YΛO)MEΘOΞY]-l-ΠΙΠΕΡΙΔΥΛΟ]ΜΕΘΥΛΟ]ΘΕΙΑΖΟΛ-2-ΥΛΟ]ΑΚΕΤΑΜΙΔΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ OGA
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
CY1124084T1 (el) Αμιδο-υποκατεστημενα παραγωγα πυριδινυλοτριαζολης και χρησεις αυτων
EA202091491A1 (ru) Новые бензиламинозамещенные пиридопиримидиноны и производные в качестве ингибиторов sos1
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
EA202190681A1 (ru) Амиды диметиламиноазетидина в качестве jak ингибиторов
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
EA202191286A1 (ru) Ингибитор 15-pgdh
CY1114521T1 (el) Ενωσεις βενζαμιδιου χρησιμες ως αναστολεις αποακετυλασων ιστονων
EA202190686A1 (ru) 5-7-членные гетероциклические амиды в качестве ингибиторов jak
EA202191239A1 (ru) Соединения и их применение для лечения дефицита 1-антитрипсина
CY1124907T1 (el) Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
EA202191114A1 (ru) Производные пиридинилсульфонамида, фармацевтические композиции и их применение
EA201692298A1 (ru) Производные карбоксамидов
EA202190057A1 (ru) Солюбилизированные апиразы, способы и применение
EA202190064A1 (ru) Цианотриазоловые соединения и варианты их применения
EA202090164A1 (ru) Изотретиноиновые перорально-слизистые композиции и способы их применения
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
JOP20190278A1 (ar) مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
EA202190452A1 (ru) Ингибиторы cdk8/19
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.